At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to the Poster presentation session. Dr. Aaron Holmes presented the poster ...

Cluster 4/5 was treated with the dual ICI regimen of ipilimumab plus nivolumab. This arm remains open to accrual. Clusters 3, 6, and 7 were excluded from the study. Additional secondary endpoints are ...

The potent and selective HIF-2a inhibitor belzutifan is a treatment option for advanced RCC following prior anti-PD- (L)1 and VEGFR-TKI therapy and may be a highly suitable candidate for novel triplet ...

Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with ...

As an example, the ALPACA trial took 6.5 years to recruit just 25 patients across three Canadian centers, underscoring the ...

The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September ...

Rathkopf presented the Late-breaking abstract 91 - Patient-reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus ...

There is a need to understand phenotype-specific therapies for interstitial cystitis/bladder pain syndrome (IC/BPS) at the clinical trial level to move beyond trial ...

Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract," by Dan Lundh, Hans Hedelin, and Dennis Larsson ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...